NCT00615927已完成2 期
Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent / Progressive Grade II Low-Grade Glioma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 64
- 试验地点
- 1
- 主要终点
- 12-month Progression Free Survival (PFS)
研究概览
简要总结
Primary objective:
- To evaluate activity of imatinib mesylate and hydroxyurea among patients with progressive/recurrent grade II low-grade glioma (LGG) as measured by 12-month progression free survival
Secondary objectives:
- To evaluate progression-free survival (PFS), overall survival and objective response rate among patients with progressive/recurrent grade II LGG treated with imatinib mesylate plus hydroxyurea
- To assess safety and tolerability of imatinib mesylate + hydroxyurea in this population
详细描述
This is an open-label, single stage, uncontrolled, non-randomized Phase II study of continuous, daily doses of imatinib mesylate & hydroxyurea in adult patients with progressive/recurrent Grade II low-grade glioma (LGG). The treatment cycle is defined as imatinib mesylate & hydroxyurea administered daily for 28 days for purpose of scheduling evaluations. All patients who receive 1 or more doses of either imatinib mesylate or hydroxyurea will be evaluable for toxicity, whereas all patients who receive a minimum of 14 consecutive days of study regimen will be evaluable for response. Patients who discontinue therapy prior to receiving 14 consecutive days of study regimen will be regarded as ineligible for evaluation of response and will be replaced.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Patients with grade II LGG that is recurrent/progressive following prior surgical resection while on non-decreasing dose of corticosteroids
- •> 25percent enlargement of bidimensional measure/new lesions on sequential imaging new &/or worsening neurologic deficits
- •Patients with progressive/recurrent optic pathway tumors
- •Patients have measurable disease on MRI/CT
- •Interval of > 4 wks between prior external beam radiation therapy (XRT)/chemo,& enrollment on protocol unless there is unequivocal evidence of tumor progression & patient has recovered from all expected toxicities associated with prior therapy. Patients treated w chemo agents such as VP-16 who would normally be retreated after shorter intervals may be treated at usual starting time even if < 4 wks from last prior dose of chemo
- •Patients not have had tumor biopsy < 1 wk/surgical resection < 2 wks prior to starting study drug
- •Patients enrolling on arm B must be on > 1 enzyme inducing anticonvulsants for >2 wks prior to starting study drug
- •Patients should be on non-increasing dose of steroids for > 7 days prior to obtaining baseline Gd-MRI of brain
- •Patients should be on non-increasing dose of steroids for > 7 days prior to starting study drug
- •Multifocal disease is eligible
- •Age > 18 yrs old
- •Karnofsky Performance Status (KPS) of > 60
- •absolute neutrophil count (ANC) > 1.5 x 10 9/L
- •Hgb > 9 g/dL
- •Platelets > 100 x 10 9/L
- •K ≥ lower limit of normal (LLN)/correctable with supplements
- •Ca ≥ LLN/correctable with supplements
- •P ≥ LLN/correctable with supplements
- •aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) & Alanine transaminase (ALT)/ Serum Glutamic Pyruvate Transaminase (SGPT} < 2.5 x ULN
- •Serum bilirubin < 1.5 x upper limit of normal (ULN)
- •Serum creatinine < 1.5 x ULN/measured 24hr Creatinine Clearance > 50 mL/min/1.73m2
- •Life expectancy ≥ 12wks
- •Written informed consent obtained prior to screening procedures
排除标准
- •Prior progressive disease/toxicity grade ≥ 3 with prior hydroxyurea therapy
- •Prior treatment with imatinib/other platelet derived growth factor (PDGF)-directed therapy
- •Excessive risk of bleeding as defined by stroke < 6 months, history of central nervous system (CNS)/intraocular bleed, or septic endocarditis
- •Evidence of intratumor hemorrhage on pretreatment diagnostic imaging, except for stable post-operative gr1 hemorrhage
- •Pregnant/breast feeding, /adults of reproductive potential not employing effective method of birth control
- •Concurrent severe and/or uncontrolled medical disease that could compromise participation in study
- •Acute/chronic liver disease
- •Confirmed diagnosis of HIV infection
- •Impairment of GI function/GI disease that may significantly alter absorption of imatinib
- •Patients taking Coumadin
- •Patients have received investigational drugs < 2wks prior to entry on study/have not recovered from toxic effects of such therapy
- •Patients have received biologic, immunotherapeutic/cytostatic agents < 1 wk prior to entry on study/have not recovered from toxic effects of such therapy
- •Patient > 5 yrs free of another primary malignancy except: if other primary malignancy is not currently clinically significant/requiring active intervention, or if other primary malignancy is basal cell skin cancer/ cervical carcinoma in situ. Existence of any other malignant disease is not allowed
- •Patients have had any surgery other than resection of brain tumor < 2 wks prior to entry on study/have not recovered from side effects of such therapy
- •Patients unwilling to/unable to comply with protocol
- •Active systemic bleeding, such as GI bleeding/gross hematuria
- •Gr2 /> peripheral edema/central/systemic fluid collections
- •Patients who enroll on arm A must have not received any EIAC for > 2 wks prior to starting study regimen
- •Any of following exclusion criteria to MRI imaging:
- •Cardiac pacemaker
- •Ferromagnetic metal implants other than those approved as safe for use in magnetic resonance (MR) scanners
- •Claustrophobia
研究组 & 干预措施
Astrocytoma
Experimental
Grade II Astrocytoma
干预措施: Imatinib Mesylate & Hydroxyurea (Drug)
Oligodendroglioma
Experimental
Grade II Oligodendroglioma or oligoastrocytomas
干预措施: Imatinib Mesylate & Hydroxyurea (Drug)
结局指标
主要结局
12-month Progression Free Survival (PFS)
时间窗: 12 months
Percentage of participants surviving twelve months from the start of cycle 1 without progression of disease. PFS was defined as the time from the cycle 1 start date to the date of the first documented progression according to modified Macdonald criteria, or to death due to any cause.
次要结局
- Median Progression-free Survival(Time in weeks from the start of cycle 1 to the date of first progression according to modified Macdonald criteria or to death due to any cause, assessed up to 156 weeks)
- Median Overall Survival (OS)(Time in weeks from the start of cycle 1 to date of death due to any cause, assessed up to 156 weeks)
- Objective Response Rate(156 weeks)
- Safety and Tolerability of Gleevec + Hydroxyurea in Patients With Low-grade Gliomas(156 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive GlioblastomaAstrocytomaGlioblastoma MultiformeNCT00154375Novartis Pharmaceuticals240
已完成
2 期
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare DiseasesLife Threatening DiseasesNCT00154388Novartis Pharmaceuticals185
已完成
2 期
Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic LeukemiaPhiladelphia Chromosome Positive Acute Lymphocytic LeukemiaNCT00154349Novartis Pharmaceuticals8
已完成
2 期
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryAcral Lentiginous Malignant MelanomaRecurrent MelanomaStage IIIA MelanomaStage IIIB MelanomaStage IIIC MelanomaStage IV MelanomaNCT00470470National Cancer Institute (NCI)30
已完成
2 期
Phase II study of imatinib mesylate for treatment of Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in children: A Japanese Cooperative TrialPhiladelphia Chromosome-positive acute lymphoblastic leukemiaJPRN-C000000290Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG)56